[Anticoagulation and chronic hemodialysis].

Area of Science:

• Nephrology
• Hematology
• Biomedical Engineering

Background:

• Hemodialysis relies on anticoagulation, historically dominated by unfractionated heparin.
• Heparin use is associated with significant risks, including hemorrhage and heparin-induced thrombocytopenia type II (HIT).
• These complications necessitate the exploration of alternative anticoagulation strategies in hemodialysis.

Purpose of the Study:

• To review and compare various anticoagulation methods used in hemodialysis.
• To highlight alternatives to heparin for patients at risk of bleeding or with HIT.
• To discuss the safety, efficacy, and cost-effectiveness of different anticoagulation options.

Main Methods:

• Review of established and emerging anticoagulation techniques for hemodialysis.
• Analysis of clinical data regarding the safety and efficacy of heparin alternatives.
• Categorization of methods including low heparin dialysis, heparin-free dialysis, regional heparinization, low molecular weight heparins, citrate, prostacyclin, nafamstat, low molecular weight heparanoid, and direct thrombin inhibitors.

Main Results:

• Heparin-free hemodialysis is recommended for patients with active hemorrhage or high bleeding risk.
• Low molecular weight heparanoid and direct thrombin inhibitors show promise for anticoagulation in HIT patients.
• Various anticoagulation methods present distinct profiles regarding safety, efficacy, and economic impact.

Conclusions:

• The development of alternative anticoagulation strategies is crucial for enhancing hemodialysis safety.
• Patient-specific risk factors, such as bleeding risk and HIT, guide the selection of appropriate anticoagulation.
• Further research into the comparative effectiveness and cost of these alternatives is warranted.